EGFR-D770>GY and Other Rare EGFR Exon 20 Insertion Mutations with a G770 Equivalence Are Sensitive to Dacomitinib or Afatinib and Responsive to EGFR Exon 20 Insertion Mutant-Active Inhibitors in Preclinical Models and Clinical Scenarios

<i>Epidermal growth factor receptor</i> (<i>EGFR</i>) exon 20 insertion mutations account for a tenth of all <i>EGFR</i> mutations in lung cancers. An important unmet clinical need is the identification of EGFR exon 20 insertion mutants that can respond to multiple classes of approved EGFR-TKIs. We...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	Ikei S. Kobayashi, Hollis Viray, Deepa Rangachari, Susumu S. Kobayashi, Daniel B. Costa
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	MDPI AG 2021-12-01
Rangatū:	Cells
Ngā marau:	lung cancer EGFR exon 20 insertion D770>GY afatinib dacomitinib poziotinib
Urunga tuihono:	https://www.mdpi.com/2073-4409/10/12/3561
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!